Swaroop Nyshadham, MD
General Practice · Lagrange, GANPI 1306892351
Payments from drug & device makers
What this record shows
AbbVie accounts for 66.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $4,835 and has fallen 89.4% since, to $512 in 2025. Among general practice clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $71.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$520
- GSK$439
- Vanda Pharmaceuticals Inc.$381
- Merck$340
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$252
- plus $566 from 10 others
Across 2 payments — averaging $137.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$275
What the payments were for
- Speaking & faculty fees$4,20057%
- Food & beverage$3,20743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $4,907 |
| AstraZeneca | 7 | $520 |
| GSK | 7 | $439 |
| Vanda Pharmaceuticals Inc. | 18 | $381 |
| Merck | 12 | $340 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $252 |
| Idorsia Pharmaceuticals US Inc | 1 | $114 |
| Currax Pharmaceuticals LLC | 5 | $80 |
| Lilly USA, LLC | 2 | $60 |
| Braeburn Inc. | 3 | $59 |
| Novo Nordisk | 3 | $57 |
| Scilex Pharmaceuticals Inc. | 1 | $57 |
| Kaleo, Inc. | 1 | $53 |
| Indivior Inc. | 2 | $51 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,407 in reported general payments places this provider in the 95th percentile of 2,542 general practice providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $36,429 |
| MounjaroTirzepatide | 34 | $35,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,031 |
| EliquisApixaban | 13 | $11,354 |
| VascepaIcosapent Ethyl | 23 | $9,264 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $4,188 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,416 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $733 |
| Ondansetron OdtOndansetron | 25 | $668 |
| Buprenorphine Hcl | 23 | $599 |
| Novolin RInsulin Regular, Human | 13 | $588 |
| Klor-Con M15Potassium Chloride | 11 | $584 |
| Atorvastatin Calcium | 74 | $547 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $498 |
| Hydrocortisone | 12 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $57 | $36,42934 claims |
| Lilly USA, LLCMounjaro | $60 | $35,69034 claims |
| GSKTrelegy Ellipta | $439 | $19,03130 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $21 | $4,78766 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,542 general practice providers in Georgia.
Other general practice in Lagrange
- Edward SchlisselMarietta$665K
- Peter VanstromTucker$424K
- Robert PauleyUnion City$155K
- Stanton McKennaAtlanta$75K
- Carlos TanGainesville$75K
- Michael BoydAugusta$67K
- Harris SiegelAtlanta$54K
- John ComisiAugusta$50K
- Jeffery BradleyLithia Springs$45K
- Ushma PatelSuwanee$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.